Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SASPject PT3.9 early-stage trial in cystic fibrosis with Pseudomonas aeruginosa lung infection
ISRCTN57413769Phase 2Not yet recruiting
- Sponsor
- SASPiPhi
- Start
- Jan 2027
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SASPject PT3.9 in Pseudomonas aeruginosa pulmonary infection and cystic fibrosis (CF) (8 arms), sponsored by SASPiPhi. Primary endpoints: Adverse events and dose-limiting toxicities, Physical examination findings and 4 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
SASPject PT3.9
03
Conditions
Pseudomonas aeruginosa pulmonary infectioncystic fibrosis (CF)
Beyond the preview
Go deeper on ISRCTN57413769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN57413769.